Correlation of Clinicopathological Factors with Brain Tumor-Related Epilepsy in Glioma

Abstract

Objectives. Glioma patients with brain tumor-related epilepsy (BTRE) have a complex profile due to the simultaneous presence of two pathologies, glioma and epilepsy; however, they have not traditionally received as much attention as those with more malignant brain tumors. The underlying pathophysiology of brain tumor-related epilepsy remains poorly understood. The purpose of this study was to investigate the possible correlation between molecular neuropathology and glioma with BTRE and a wide range of BTRE-associated molecular markers of glioma patients. Methods. A retrospective cohort study of 186 glioma patients was evaluated at our hospital, of which 64 had BTRE. The chi-square test, Spearman rank correlation, and multivariate logistic analyses were used to identify clinicopathological factors associated with BTRE in glioma patients. Results. Of the 186 patients examined in this study, 64 (34.4%) had BTRE. Based on the analysis of the characteristics of these patients, the results showed that patient age (over 40 years; P = 0.007 ), low WHO grade (grade I, II; P = 0.001 ), IDH-1 positive mutation ( P = 0.027 ), low ATR-X expression level ( OR = 0.44 ; 95% CI: 0.21, 0.92), and low Ki-67 PI ( OR = 0.25 ; 95% CI: 0.10, 0.68) were associated with the occurrence of BTRE. In our cohort, BTRE patients did not differ by sex, tumor location, or expression of olig-2 and CD34. The results of the matching study showed that low Ki-67 PI and negative ATR-X expression levels were independent factors for a higher incidence of preoperative seizures in glioma patients. Conclusion. The current study updates existing information on genetic markers in gliomas with BTRE and explores the correlation of a wide range of clinicopathological factors and glioma patients with BTRE and suggests three putative biomarkers for BTRE: positive IDH1 mutation, low Ki-67 PI, and negative ATR-X expression. These factors may provide insights for developing a more thorough understanding of the pathogenesis of epilepsy and effective treatment strategies aimed at seizure control.

Multi‐omics technologies and molecular biomarkers in brain tumor‐related epilepsy

“…Wang et al. conducted a retrospective cohort study of 186 glioma patients; 100 based on the results of the immunochemical assay, the authors showed that glioma patients with a positive variant of the ATRX gene in the non‐epilepsy group were less likely to develop epilepsy than those in the epilepsy group. You et al.…”

Thiophene‐containing compounds with antimicrobial activity

“…A series of compounds structurally related to flavonoid icariin has been obtained through the reaction of the 3‐hydroxy group of the aglycone form of icariin with various sulfonyl chlorides. [ 293 ] Of the four thiophene‐containing sulfonates 322 (Figure 37) in this collection, compound 322 (R = COOCH 3 ) was devoid of antibacterial activity, while compounds 322 (R = H or Br) had moderate antibacterial activity. Thiophene 322 (R = Cl) exhibited an overall good activity, as it was equipotent to ciprofloxacin against two MRSA strains and possessed half of the activity of ciprofloxacin against the other two MRSA strains and one methicillin‐sensitive S. aureus strain.…”

Retracted: Correlation of Clinicopathological Factors with Brain Tumor-Related Epilepsy in Glioma

“…This article has been retracted by Hindawi following an investigation undertaken by the publisher [ 1 ]. This investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process: Discrepancies in scope Discrepancies in the description of the research reported Discrepancies between the availability of data and the research described Inappropriate citations Incoherent, meaningless and/or irrelevant content included in the article Peer-review manipulation …”

“…This article has been retracted by Hindawi following an investigation undertaken by the publisher [1]. This investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process:…”